Celcuity Reports Updated Phase 1b/2 Prostate Cancer Study Data

The company reported median rPFS of 15.7 months and a six-month rPFS rate of 82.2% among patients previously treated with abiraterone. For patients previously treated with enzalutamide, median rPFS was 9.1 months and the six-month rate was 62.5%.